42Furthermore, an interpretation whereby two different salts containing the same therapeutically active part may be essentially similar for the purposes of Article 4.8 (a)(iii) of Directive 65/65 is the interpretation adopted in the guidelines published by the Commission in ‘The rules governing medicinal products in the European Community, Volume II: Notice to applicants for marketing authorisations for medicinal products for human use in the Member States of the European Community’ in its version of 1998, which was in force when Synthon and Genthon submitted applications for MA for their products.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.